Company Overview and News

 
There’s more to Samchem than chemicals

2018-08-29 theedgemarkets
RIDING on industrial production expansion and manufacturing sector growth over the past decades, Samchem Holdings Bhd has established itself as one of the largest distributors of industrial chemicals in the Asia-Pacific.
5151 5147

 
KLCI seen starting off August on a positive note, support at 1,770-level

2018-07-31 theedgemarkets
KUALA LUMPUR (Aug 1): The FBM KLCI is seen starting off August on a positive note today, in line with the overnight gains at most global markets, with support at the 1,770-point level.
5436 5216 0035 7158 5151 7022 GBTKF

 
Scomi Group, YTL Hospitality REIT, Serba Dinamik, Perstima, Globetronics, Opcom, Halex and Datasonic

2018-07-31 theedgemarkets
KUALA LUMPUR (July 31): Based on corporate announcements and news flow today, companies in focus on Wednesday (Aug 1) may include: Scomi Group Bhd, YTL Hospitality Real Estate Investment Trust (REIT), Serba Dinamik Holdings Bhd, Perusahaan Sadur Timah Malaysia Bhd, Globetronics Technology Bhd, Opcom Holdings Bhd, Halex Holdings Bhd and Datasonic Group Bhd.
SLLXF 5436 5216 4863 0035 5109 7158 HIL MYTEF 5151 7022 GBTKF

 
Halex CEO Mohd Faisal Kaim resigns

2018-07-31 theedgemarkets
KUALA LUMPUR (July 31): Mohd Faisal Kaim Abdullah has resigned as the chief executive officer of agrochemicals company Halex Holdings Bhd to pursue other interests.
5151

 
Businessman Koh Kin Lip sells shares in SCH, ceases to be substantial shareholder

2018-07-24 theedgemarkets
KUALA LUMPUR (July 24): Low-profile businessman Tan Sri Richard Koh Kin Lip, Chow Dai Ying and SCH Group Bhd's directors Koh Chen Foong and Liew Fook Meng have ceased to be substantial shareholders of the quarry-based products and machinery group following the disposal of 68 million shares or a 13.19% stake for RM11.56 million or 17 sen per share yesterday.
7205 5151 BSMAF 0161 1818

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...